Two Investigational Meds Promising for Myasthenia Gravis Two Investigational Meds Promising for Myasthenia Gravis
Two investigational medications are safe and effective for the treatment of generalized myasthenia gravis, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 16, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours. Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities. It is a blue-black coloration that shows a normal skin undertone when palpated. This is the second in a short case series of differential diagnoses of colored skin conditions. An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Ultomiris Approved in the US for Adults with Generalised Myasthenia Gravis
First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 28, 2022 Category: Drugs & Pharmacology Source Type: news

Myasthenia Gravis: Better Version of Eculizumab on the Horizon
(MedPage Today) -- SEATTLE -- An agent that works similarly to the approved myasthenia gravis (MG) drug eculizumab (Soliris) but with a longer dosing interval, and made by the same company, proved its mettle in a pivotal study, a researcher said... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 6, 2022 Category: Neurology Source Type: news

Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug
The novel self-administered subcutaneous peptide inhibitor zilucoplan met the primary and all secondary endpoints in a phase 3 study of adults with generalized myasthenia gravis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 5, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

FDA Approves First-in-Class Treatment for Myasthenia Gravis
TUESDAY, Dec. 21, 2021 -- Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2021 Category: Pharmaceuticals Source Type: news

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases Merck to accelerate development of Chord's innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Op... Biopharmaceuticals, Neurology, Mergers & Acquisitions Chord Therapeutics, Merck (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 20, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves New Myasthenia Gravis Drug FDA Approves New Myasthenia Gravis Drug
Efgartigimod is an antibody fragment designed to reduce pathogenic IgG antibodies and block the IgG recycling process in patients with generalized myasthenia gravis.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 18, 2021 Category: Primary Care Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
Breda, the Netherlands—Dec. 17, 2021 - argenx SE (Euronext& Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 17, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Myasthenia Gravis
Today, the FDA approved Vyvgart for the treatment of generalized myasthenia gravis in certain adults (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Sharing Mayo Clinic: Reversing a dire disorder on the road to renewed health
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease. When Lorinda McKinley arrived at Mayo Clinic ’s Spine Center in February seeking a second opinion for neck surgery, her eyelids were droopy, her jaw routinely fell open, and she couldn’t lift her arms above her head. Based on the results of an… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 14, 2021 Category: Databases & Libraries Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fluctuating Decision-Making in People with Mental Illness
Robert was an older man who lived independently and worked full time. He was diagnosed simultaneously with metastatic cancer and myasthenia gravis, an autoimmune neuromuscular disorder that causes muscle weakness in the eyes, face, and throat. Due to his cancer, the only treatment available was high-dose steroids. While his strength improved, he was later hospitalized with steroid-induced psychosis. He was discharged to an assisted living community where he fluctuated between days of psychosis – demanding to leave – with periods of lucidity marked by sincere remorse and understanding of his care needs. (Source: Caring for the Ages)
Source: Caring for the Ages - October 24, 2021 Category: Health Management Authors: Omid Salaami, Katja Elbert-Avila Tags: Ethics Source Type: news

ICER releases draft evidence report on cost effectiveness of myasthenia gravis treatments
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis
This case reviews the diagnostic workup and management of a patient with severe immune-related adverse effects due to the immune checkpoint inhibitor durvalumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news